DNA methylation as a triage tool for cervical cancer screening - A meeting report.
Prev Med Rep
; 41: 102678, 2024 May.
Article
in En
| MEDLINE
| ID: mdl-38524273
ABSTRACT
Introduction:
DNA methylation is proposed as a novel biomarker able to monitor molecular events in human papillomavirus (HPV) infection pathophysiology, enabling the distinction between HPV-induced lesions with regression potential from those that may progress to HPV-related cancer.Methods:
This meeting report summarises the presentations and expert discussions during the HPV Prevention and Control Board-focused topic technical meeting on DNA methylation validation in clinician-collected and self-collected samples, novel DNA methylation markers discovery, implementation in cervical cancer screening programs, and their potential in women living with human immunodeficiency virus (HIV).Results:
Data presented in the meeting showed that HPV-positive, baseline methylation-negative women have a lower cumulative cervical cancer incidence than baseline cytology-negative women, making DNA methylation an attractive triage strategy. However, additional standardised data in different settings (low- versus high-income settings), samples (clinician-collected and self-collected), study designs (prospective, modelling, impact) and populations (immunocompetent women, women living with HIV) are needed.Conclusion:
Establishing international validation guidelines were identified as the way forward towards accurate validation and subsequent implementation in current screening programs.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
Prev Med Rep
Year:
2024
Type:
Article
Affiliation country:
Belgium